昼夜节律紊乱在帕金森病睡眠障碍中的机制研究进展
Research Progress on Mechanisms of Circadian Rhythm Disruption in Sleep Disorders of Parkinson’s Disease
DOI: 10.12677/acm.2026.1672670, PDF,   
作者: 高 源:成都中医药大学临床医学院,四川 成都;梁静涛*:成都中医药大学附属医院神经内科,四川 成都
关键词: 帕金森病昼夜节律睡眠障碍机制Parkinson’s Disease Circadian Rhythm Sleep Disorders Mechanism
摘要: 帕金森病(Parkinson’s disease, PD)睡眠障碍患病率高,与α-突触核蛋白(α-syn)病理形成恶性循环。近年证据表明,昼夜节律紊乱是PD睡眠障碍的核心病理基础。本文系统梳理PD睡眠障碍相关的昼夜节律紊乱,从临床特征(静息–活动节律碎片化、核心体温与褪黑素及皮质醇节律异常)、分子机制(Bmal1/Clock等核心时钟基因表达异常及多巴胺能神经元节律调控)、双向病理关系(节律紊乱促进α-syn聚集,α-syn沉积损伤视交叉上核及节律脑区)以及神经环路基础(SCN-下丘脑–脑干睡眠–觉醒网络)四个层面进行整合分析,归纳出时钟基因/SCN功能退化、神经内分泌节律紊乱与节律-α-syn正反馈循环相互叠加的机制框架,并展望了时间疗法在PD睡眠障碍管理中的潜在应用价值。
Abstract: Sleep disorders are highly prevalent in Parkinson’s disease (PD) and form a vicious cycle with α-synuclein (α-syn) pathology. Emerging evidence indicates that circadian rhythm disruption is a core pathological basis of PD-related sleep disturbances. This review systematically examines circadian rhythm abnormalities associated with sleep disorders in PD, integrating evidence from four levels: clinical features (fragmentation of rest-activity rhythms, abnormalities in core body temperature, melatonin, and cortisol rhythms); molecular mechanisms (dysregulation of core clock genes such as Bmal1/Clock and their modulation of dopaminergic neuron rhythmicity); bidirectional pathological interactions (circadian disruption promoting α-syn aggregation, and α-syn deposition damaging the suprachiasmatic nucleus and other circadian brain regions); and neural circuit basis (the SCN-hypothalamus-brainstem sleep-wake network). Based on these findings, we propose an integrative framework in which clock gene/SCN dysfunction, neuroendocrine rhythm disruption, and a positive feedback loop between circadian dysregulation and α-syn pathology mutually reinforce each other. Finally, we discuss the potential application of chronotherapy in the management of sleep disorders in PD.
文章引用:高源, 梁静涛. 昼夜节律紊乱在帕金森病睡眠障碍中的机制研究进展[J]. 临床医学进展, 2026, 16(7): 1503-1514. https://doi.org/10.12677/acm.2026.1672670

参考文献

[1] Liu, J., Tong, Y., Qu, X., Liu, Y., Liu, X. and Zheng, J. (2025) Evaluation of Disease Burden in Parkinson’s Disease for Individuals Aged 60 and Older. Neuroepidemiology. [Google Scholar] [CrossRef
[2] Maggi, G., Vitale, C., Cerciello, F. and Santangelo, G. (2023) Sleep and Wakefulness Disturbances in Parkinson’s Disease: A Meta-Analysis on Prevalence and Clinical Aspects of REM Sleep Behavior Disorder, Excessive Daytime Sleepiness and Insomnia. Sleep Medicine Reviews, 68, Article ID: 101759. [Google Scholar] [CrossRef] [PubMed]
[3] Duan, X., Liu, H., Hu, X., Yu, Q., Kuang, G., Liu, L., et al. (2024) Insomnia in Parkinson’s Disease: Causes, Consequences, and Therapeutic Approaches. Molecular Neurobiology, 62, 2292-2313. [Google Scholar] [CrossRef] [PubMed]
[4] Wang, S., Yuan, R., Wang, W., Peng, Y., Hu, K., He, W., et al. (2026) Spike RBD Drives Sustained Parkinson’s Disease Progression via Microglia-Neuron Crosstalk-Mediated RTP801 Upregulation. Journal of Advanced Research, 83, 315-332. [Google Scholar] [CrossRef] [PubMed]
[5] Breen, D.P., Vuono, R., Nawarathna, U., Fisher, K., Shneerson, J.M., Reddy, A.B., et al. (2014) Sleep and Circadian Rhythm Regulation in Early Parkinson Disease. JAMA Neurology, 71, 589-595. [Google Scholar] [CrossRef] [PubMed]
[6] Chaurasia, R.N., Ohia, S. and Bagchi, D. (2024) A Review on Diverse Neurological Disorders. Elsevier.
[7] Turkistani, A., Al-kuraishy, H.M., Al-Gareeb, A.I., Negm, W.A., Bahaa, M.M., Metawee, M.E., et al. (2024) Blunted Melatonin Circadian Rhythm in Parkinson’s Disease: Express Bewilderment. Neurotoxicity Research, 42, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[8] Niwa, F., Kuriyama, N., Nakagawa, M. and Imanishi, J. (2011) Circadian Rhythm of Rest Activity and Autonomic Nervous System Activity at Different Stages in Parkinson’s Disease. Autonomic Neuroscience, 165, 195-200. [Google Scholar] [CrossRef] [PubMed]
[9] Wu, J.Q., Li, P., Stavitsky Gilbert, K., Hu, K. and Cronin‐Golomb, A. (2018) Circadian Rest‐Activity Rhythms Predict Cognitive Function in Early Parkinson’s Disease Independently of Sleep. Movement Disorders Clinical Practice, 5, 614-619. [Google Scholar] [CrossRef] [PubMed]
[10] Leng, Y., Blackwell, T., Cawthon, P.M., Ancoli-Israel, S., Stone, K.L. and Yaffe, K. (2020) Association of Circadian Abnormalities in Older Adults with an Increased Risk of Developing Parkinson Disease. JAMA Neurology, 77, 1270-1278. [Google Scholar] [CrossRef] [PubMed]
[11] Raupach, A.K., Ehgoetz Martens, K.A., Memarian, N., Zhong, G., Matar, E., Halliday, G.M., et al. (2019) Assessing the Role of Nocturnal Core Body Temperature Dysregulation as a Biomarker of Neurodegeneration. Journal of Sleep Research, 29, e12939. [Google Scholar] [CrossRef] [PubMed]
[12] Suram, R.P., Fatima, R., Madhuvilakku, R., Jung, J.H., Kim, S.J. and Hong, Y. (2025) Dysregulation of Melatonin Rhythm in Parkinson’s and Huntington’s Disease: A Systematic Review and Meta-Analysis. Frontiers in Aging Neuroscience, 17, Article 1637881. [Google Scholar] [CrossRef
[13] Hartmann, A., Veldhuis, J.D., Deuschle, M,. et al. (1997) Twenty-Four Hour Cortisol Release Profiles in Patients with Alzheimer’s and Parkinson’s Disease Compared to Normal Controls. Neuroendocrinology, 66, 296-305.
[14] Feng, L.W., Jia, M.X., Liu, T.T., Cheng, X.S. and Wei, J.S. (2026) Parkinson’s Disease: When the Gears of Time Stiffen—The Life-and-Death Game of Circadian Rhythms, Sleep Disorders, and Neurodegeneration. Genes & Diseases.
[15] Guillot, S.J., Luppi, P., Dupuis, L. and Bolborea, M. (2025) Sleep in Neurodegenerative Diseases: A Focus on Melatonin, Melanin‐Concentrating Hormone and Orexin. Journal of Neuroendocrinology, 37, e70085. [Google Scholar] [CrossRef
[16] 刘春风, 王亚丽. 帕金森病患者生物节律紊乱的研究进展[J]. 中华神经科杂志, 2017, 50(7): 481-483.
[17] Takahashi, J.S. (2016) Transcriptional Architecture of the Mammalian Circadian Clock. Nature Reviews Genetics, 18, 164-179. [Google Scholar] [CrossRef] [PubMed]
[18] Li, T., Cheng, C., Jia, C., Leng, Y., Qian, J., Yu, H., et al. (2021) Peripheral Clock System Abnormalities in Patients with Parkinson’s Disease. Frontiers in Aging Neuroscience, 13, Article 736026. [Google Scholar] [CrossRef] [PubMed]
[19] Marano, M., Rosati, J., Magliozzi, A., Casamassa, A., Rappa, A., Sergi, G., et al. (2023) Circadian Profile, Daytime Activity, and the Parkinson’s Phenotype: A Motion Sensor Pilot Study with Neurobiological Underpinnings. Neurobiology of Sleep and Circadian Rhythms, 14, Article ID: 100094. [Google Scholar] [CrossRef] [PubMed]
[20] Liu, W., Wei, S., Huang, G., Liu, L., Gu, C., Shen, Y., et al. (2020) BMAL1 Regulation of Microglia‐Mediated Neuroinflammation in MPTP‐Induced Parkinson’s Disease Mouse Model. The FASEB Journal, 34, 6570-6581. [Google Scholar] [CrossRef] [PubMed]
[21] Swaroop, A., Paul, J.R., McMeekin, L.J., Barnett, A.M., Colafrancesco, A.M., Russell, D.L., et al. (2025) The Molecular Clock Drives Motivated Locomotion and Time-of-Day-Dependent Firing Patterns in Mouse Dopaminergic Neurons. npj Biological Timing and Sleep, 2, Article No. 28. [Google Scholar] [CrossRef] [PubMed]
[22] Lou, F., Li, M., Ren, Y., Luo, X., Liu, N. and Li, X. (2017) CLOCK Rs1801260 Polymorphism Is Associated with Susceptibility to Parkinson’s Disease in a Chinese Population. Neuroscience Bulletin, 33, 734-736. [Google Scholar] [CrossRef] [PubMed]
[23] Kalinderi, K., Papaliagkas, V. and Fidani, L. (2024) The Genetic Landscape of Sleep Disorders in Parkinson’s Disease. Diagnostics, 14, Article 106. [Google Scholar] [CrossRef] [PubMed]
[24] Pacelli, C., Rotundo, G., Lecce, L., Menga, M., Bidollari, E., Scrima, R., et al. (2019) Parkin Mutation Affects Clock Gene-Dependent Energy Metabolism. International Journal of Molecular Sciences, 20, Article 2772. [Google Scholar] [CrossRef] [PubMed]
[25] Deng, R., Liu, C., Jin, H., Cao, Y., Wang, L., Zhang, Y., et al. (2025) Circadian Disruption Exacerbates Cognitive Impairment via an Intense Neuroinflammatory Reaction and Alpha-Synuclein Deposition in a Parkinson’s Disease Mouse Model. NeuroReport, 36, 640-650. [Google Scholar] [CrossRef] [PubMed]
[26] Yalçin, M., Grande, V., Outeiro, T.F. and Relógio, A. (2025) Circadian Clock Dysfunction in Parkinson’s Disease: Mechanisms, Consequences, and Therapeutic Strategy. npj Parkinsons Disease, 11, Article No. 213. [Google Scholar] [CrossRef] [PubMed]
[27] Ukraintseva, Y.V. and Kovalzon, V.M. (2016) Circadian Regulation and Its Disorders in Parkinson’s Disease Patients. Part 2: Experimental Models, α-Synuclein, and Melatonin. Human Physiology, 42, 559-570. [Google Scholar] [CrossRef
[28] De Pablo-Fernández, E., Courtney, R., Warner, T.T. and Holton, J.L. (2018) A Histologic Study of the Circadian System in Parkinson Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy. JAMA Neurology, 75, 1008-1012. [Google Scholar] [CrossRef] [PubMed]
[29] Kudo, T., Loh, D.H., Truong, D., Wu, Y. and Colwell, C.S. (2011) Circadian Dysfunction in a Mouse Model of Parkinson’s Disease. Experimental Neurology, 232, 66-75. [Google Scholar] [CrossRef] [PubMed]
[30] Li, Y., Xia, Y., Yin, S., Wan, F., Hu, J., Kou, L., et al. (2021) Targeting Microglial α-Synuclein/TLRs/NF-κB/NLRP3 Inflammasome Axis in Parkinson’s Disease. Frontiers in Immunology, 12, Article 719807. [Google Scholar] [CrossRef] [PubMed]
[31] Kou, L., Chi, X., Sun, Y., Han, C., Wan, F., Hu, J., et al. (2022) The Circadian Clock Protein Rev-Erbα Provides Neuroprotection and Attenuates Neuroinflammation against Parkinson’s Disease via the Microglial NLRP3 Inflammasome. Journal of Neuroinflammation, 19, Article No. 133. [Google Scholar] [CrossRef] [PubMed]
[32] Wang, Y., Lv, D., Liu, W., Li, S., Chen, J., Shen, Y., et al. (2018) Disruption of the Circadian Clock Alters Antioxidative Defense via the SIRT1‐BMAL1 Pathway in 6‐OHDA‐Induced Models of Parkinson’s Disease. Oxidative Medicine and Cellular Longevity, 2018, Article ID: 4854732. [Google Scholar] [CrossRef] [PubMed]
[33] Namgyal, D. and Lim, C. (2025) Circadian Rhythm Dysfunction in Neurodegenerative Diseases: A Bidirectional Perspective and Therapeutic Potential. Nature and Science of Sleep, 17, 2969-2989. [Google Scholar] [CrossRef
[34] Dutta, D., Jana, M., Majumder, M., Mondal, S., Roy, A. and Pahan, K. (2021) Selective Targeting of the TLR2/MyD88/NF-κB Pathway Reduces Α-Synuclein Spreading in Vitro and in Vivo. Nature Communications, 12, Article No. 5382. [Google Scholar] [CrossRef] [PubMed]
[35] Huang, J. and Li, W. (2024) Molecular Crosstalk between Circadian Clock and NLRP3 Inflammasome Signaling in Parkinson’s Disease. Heliyon, 10, e24752. [Google Scholar] [CrossRef] [PubMed]
[36] Iovino, M., Messana, T., De Pergola, G., Iovino, E., Guastamacchia, E., Giagulli, V.A., et al. (2019) Vigilance States: Central Neural Pathways, Neurotransmitters and Neurohormones. Endocrine, Metabolic & Immune DisordersDrug Targets, 19, 26-37. [Google Scholar] [CrossRef] [PubMed]
[37] Saper, C.B. and Fuller, P.M. (2017) Wake-Sleep Circuitry: An Overview. Current Opinion in Neurobiology, 44, 186-192. [Google Scholar] [CrossRef] [PubMed]
[38] Grippo, R.M., Purohit, A.M., Zhang, Q., Zweifel, L.S. and Güler, A.D. (2017) Direct Midbrain Dopamine Input to the Suprachiasmatic Nucleus Accelerates Circadian Entrainment. Current Biology, 27, 2465-2475.e3. [Google Scholar] [CrossRef] [PubMed]
[39] Mesgar, S., Jameie, S.B., Aliaghaei, A., Parvardeh, S., Torabi, A. and Haghparast, A. (2021) Dopamine D1 Receptor-Mediated Regulation of Per1, Per2, CLOCK, and BMAL1 Expression in the Suprachiasmatic Nucleus in Adult Male Rats. Journal of Molecular Neuroscience, 72, 618-625. [Google Scholar] [CrossRef] [PubMed]
[40] Grippo, R.M. and Güler, A.D. (2019) Dopamine Signaling in Circadian Photoentrainment: Consequences of Desynchrony. Yale Journal of Biology and Medicine, 92, 271-281.
[41] Arendt, J. (2005) Melatonin: Characteristics, Concerns, and Prospects. Journal of Biological Rhythms, 20, 291-303. [Google Scholar] [CrossRef] [PubMed]
[42] Fifel, K. and DeBoer, T. (2015) The Central Clock in Patients with Parkinson Disease. JAMA Neurology, 71, 1456-1457.
[43] Pérez-Lloret, S. and Cardinali, D.P. (2021) Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson’s Disease. Frontiers in Pharmacology, 12, Article 650597. [Google Scholar] [CrossRef] [PubMed]
[44] Videnovic, A., Noble, C., Reid, K.J., Peng, J., Turek, F.W., Marconi, A., et al. (2014) Circadian Melatonin Rhythm and Excessive Daytime Sleepiness in Parkinson Disease. JAMA Neurology, 71, 463-469. [Google Scholar] [CrossRef] [PubMed]
[45] Gros, P. and Videnovic, A. (2020) Overview of Sleep and Circadian Rhythm Disorders in Parkinson Disease. Clinics in Geriatric Medicine, 36, 119-130. [Google Scholar] [CrossRef] [PubMed]
[46] Cardinali, D.P., Brown, G.M. and Pandi-Perumal, S.R. (2021) Chronotherapy. In: Swaab, D.F., Kreier, F., Lucassen, P.J., et al., Eds., The Human Hypothalamus: Anterior Region, Elsevier, 357-369.
[47] Gilat, M., Coeytaux Jackson, A., Marshall, N.S., Hammond, D., Mullins, A.E., Hall, J.M., et al. (2019) Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease: A Randomised Controlled Trial. Movement Disorders, 35, 344-349. [Google Scholar] [CrossRef] [PubMed]
[48] Ahn, J.H., Kim, M., Park, S., Jang, W., Park, J., Oh, E., et al. (2020) Prolonged-Release Melatonin in Parkinson’s Disease Patients with a Poor Sleep Quality: A Randomized Trial. Parkinsonism & Related Disorders, 75, 50-54. [Google Scholar] [CrossRef] [PubMed]
[49] Dowling, G.A., Mastick, J., Colling, E., et al. (2005) Melatonin for Sleep Disturbances in Parkinson’s Disease. Sleep Medicine, 6, 459-466.
[50] Zrineh, A., Akwan, R., Elsharkawy, M.M., Douden, B., Sleibi, W. and Eldesouki, M. (2025) The Effect of Melatonin on Sleep Quality and Daytime Sleepiness in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Sleep Medicine, 131, 106540. [Google Scholar] [CrossRef] [PubMed]
[51] Yousef, O., Abouelmagd, M., Khaddam, H., Shbani, A., Yousef, R., Meshref, M., et al. (2026) Efficacy of Melatonin for Sleep Disturbances in Parkinson’s Disease: Systematic Review and Meta-Analysis. (p6-17.005). Neurology, 106, Article No. 1205. [Google Scholar] [CrossRef
[52] Huang, H., Huang, T. and Hong, C. (2021) Bright Light Therapy for Parkinson Disease: A Literature Review and Meta-Analysis of Randomized Controlled Trials. Biology, 10, Article 1205. [Google Scholar] [CrossRef] [PubMed]
[53] Videnovic, A., Klerman, E.B., Wang, W., Marconi, A., Kuhta, T. and Zee, P.C. (2017) Timed Light Therapy for Sleep and Daytime Sleepiness Associated with Parkinson Disease: A Randomized Clinical Trial. JAMA Neurology, 74, 411-418. [Google Scholar] [CrossRef] [PubMed]
[54] Paus, S., Schmitz‐Hübsch, T., Wüllner, U., Vogel, A., Klockgether, T. and Abele, M. (2007) Bright Light Therapy in Parkinson’s Disease: A Pilot Study. Movement Disorders, 22, 1495-1498. [Google Scholar] [CrossRef] [PubMed]
[55] Willis, G.L. and Armstrong, S.M. (2023) Fine-Tuning the Circadian System with Light Treatment for Parkinson’s Disease: An In-Depth, Critical Review. Reviews in the Neurosciences, 35, 57-84. [Google Scholar] [CrossRef] [PubMed]
[56] Obayashi, K., Saeki, K., Tai, Y., Yamagami, Y., Esaki, Y., Yoshikawa, T., et al. (2024) Daily Light Exposure Profiles and the Association with Objective Sleep Quality in Patients with Parkinson’s Disease: The PHASE Study. SLEEP, 47, zsae036. [Google Scholar] [CrossRef] [PubMed]
[57] Feigl, B., Lewis, S.J.G., Burr, L.D., Schweitzer, D., Gnyawali, S., Vagenas, D., et al. (2024) Efficacy of Biologically-Directed Daylight Therapy on Sleep and Circadian Rhythm in Parkinson’s Disease: A Randomised, Double-Blind, Parallel-Group, Active-Controlled, Phase 2 Clinical Trial. eClinicalMedicine, 69, Article ID: 102474. [Google Scholar] [CrossRef] [PubMed]
[58] Fifel, K. and Videnovic, A. (2019) Chronotherapies for Parkinson’s Disease. Progress in Neurobiology, 174, 16-27. [Google Scholar] [CrossRef] [PubMed]
[59] Gonçalves, B.S.B., Cavalcantib, P.R.A., Tavaresb, G.R., Campos, T.F. and Araujo, J.F. (2014) Nonparametric Methods in Actigraphy: An Update. Sleep Science, 07, 158-164. [Google Scholar] [CrossRef
[60] Collins, F.S. and Varmus, H. (2015) A New Initiative on Precision Medicine. New England Journal of Medicine, 372, 793-795. [Google Scholar] [CrossRef] [PubMed]
[61] Yalçin, M., Peralta, A.R., Bentes, C., Silva, C., Guerreiro, T., Ferreira, J.J., et al. (2024) Molecular Characterization of the Circadian Clock in Patients with Parkinson’s Disease–clock4pd Study Protocol. PLOS ONE, 19, e0305712. [Google Scholar] [CrossRef] [PubMed]
[62] Okyere, S.K., Zeng, C., Yue, D. and Hu, Y. (2021) Neurotoxic Mechanism and Shortcomings of MPTP, 6-OHDA, Rotenone and Paraquat-Induced Parkinson’s Disease Animal Models. Venoms and Toxins, 1, 27-40. [Google Scholar] [CrossRef
[63] Carpi, M. and Liguori, C. (2025) Circadian and Sleep-Wake Rhythm Alterations in Isolated REM Sleep Behavior Disorder: Biomarkers of Prodromal α-Synucleinopathy. Frontiers in Neuroscience, 19, Article 1727683. [Google Scholar] [CrossRef
[64] Kataoka, H., Saeki, K., Sugie, K. and Obayashi, K. (2026) Circadian Disruption and Its Clinical Implications in Parkinson’s Disease: A Narrative Review. Sleep Medicine, 143, Article ID: 108928. [Google Scholar] [CrossRef
[65] Yao, T. and Kim, R. (2025) Mathematical Modeling of Dopamine Rhythms and Timing of Dopamine Reuptake Inhibitors. PLOS Computational Biology, 21, e1013508. [Google Scholar] [CrossRef
[66] Foltynie, T., Gandhi, S. and Carroll, C. (2026) Evolution of Disease Modifying Therapy Clinical Trial Design and Therapeutic Endpoints for Parkinson’s Disease. Journal of Parkinsons Disease. [Google Scholar] [CrossRef
[67] Majbour, N.K., Vaikath, N.N., Eusebi, P., Chiasserini, D., Ardah, M., Varghese, S., et al. (2016) Longitudinal Changes in CSF α‐Synuclein Species Reflect Parkinson’s Disease Progression. Movement Disorders, 31, 1535-1542. [Google Scholar] [CrossRef] [PubMed]
[68] Lenka, A. and Jankovic, J. (2023) How Should Future Clinical Trials Be Designed in the Search for Disease-Modifying Therapies for Parkinson’s Disease? Expert Review of Neurotherapeutics, 23, 107-122. [Google Scholar] [CrossRef] [PubMed]